Abiomed, Inc. (ABMD) Tops Q2 Views; Reaffirms FY12 Outlook

November 3, 2011 7:10 AM EDT
Abiomed, Inc. (NASDAQ: ABMD) reported Q2 EPS of $0.09, $0.18 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $27.7 million.

The stock was halted to report the results.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Trading Halts